Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

SAIT301

Known as: Anti-C-met Monoclonal Antibody SAIT301 
A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase I Trial of Anti‐MET Monoclonal Antibody in MET‐Overexpressed Refractory Cancer
Background Samsung Advance Institute of Technology‐301 (SAIT301) is a human immunoglobulin G2 antibody that can specifically… 
  • table 1
  • figure 1
  • table 2
  • table 2
  • figure 2
2015
2015
Abstract 661: Increasing sensitivity of SAIT301, a specific monoclonal antibody of c-Met, with paclitaxel combination in c-Met positive gastric cancer
The c-Met is frequently overexpressed and related to a worse prognosis in gastric carcinoma (GC). This study aimed to determine a… 
2015
2015
Abstract 662: USP8 modulates ubiquitination of LRIG1 for Met degradation
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a… 
2014
2014
Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression
Nasopharyngeal carcinoma (NPC) is a common malignant tumor with high invasive and metastatic potential. The hepatocyte growth… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2014
Highly Cited
2014
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
USP8 modulates ubiquitination of LRIG1 for Met degradation
The Met receptor tyrosine kinase is an attractive target for cancer therapy as it promotes invasive tumor growth. SAIT301 is a… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Abstract LB-219: Synthetic lethal screening reveals FGFR as one of combinatorial targets to overcome resistance to Met-targeted therapy
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Met is a receptor tyrosine kinase that promotes cancer… 
2014
2014
298 Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression
2013
2013
Abstract 1036: Cbl-independent degradation of Met: Ways to avoid agonism of bivalent Met targeting antibody.
The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE